Presentation is loading. Please wait.

Presentation is loading. Please wait.

Association of total disease burden and disease progression with age‐adjusted blood heteroplasmy Association of total disease burden and disease progression.

Published byRandall Wheeler Modified over 5 years ago

Similar presentations

Presentation on theme: "Association of total disease burden and disease progression with age‐adjusted blood heteroplasmy Association of total disease burden and disease progression."— Presentation transcript:

1 Association of total disease burden and disease progression with age‐adjusted blood heteroplasmy
Association of total disease burden and disease progression with age‐adjusted blood heteroplasmy Points are coloured according to mean age‐adjusted blood heteroplasmy level. Dashed lines and shading represent scores and 95% confidence intervals predicted using a linear model (with the square root of NMDAS score as the dependent variable and age and age‐adjusted blood heteroplasmy as independent variables) for individuals with 10% (blue), 50% (orange) and 90% (red) heteroplasmy levels. Association of total disease burden with age‐adjusted blood heteroplasmy. Points represent mean NMDAS score per individual.Association of and disease progression with age‐adjusted blood heteroplasmy. Each point represents one NMDAS assessment with points from each individual connected by a solid line (N = 210). John P Grady et al. EMBO Mol Med. 2018;10:e8262 © as stated in the article, figure or figure legend

Download ppt "Association of total disease burden and disease progression with age‐adjusted blood heteroplasmy Association of total disease burden and disease progression."

Similar presentations

3.7 Graphing Inequalities In Two Variables. Get y by itself Graph If ≤ or ≥: use solid line If : use dashed line If < or ≤: shade below the line If >

3.7 Graphing Inequalities In Two Variables. Get y by itself Graph If ≤ or ≥: use solid line If : use dashed line If < or ≤: shade below the line If >
EXAMPLE 4 Graph a linear inequality in one variables Graph the inequality y  –3. SOLUTION Graph the equation y = –3. The inequality is , so use a solid.

EXAMPLE 4 Graph a linear inequality in one variables Graph the inequality y  –3. SOLUTION Graph the equation y = –3. The inequality is , so use a solid.
Graph linear inequalities with one variable EXAMPLE 2 Graph ( a ) y < –3 and ( b ) x < 2 in a coordinate plane. Test the point (0,0). Because (0,0) is.

Graph linear inequalities with one variable EXAMPLE 2 Graph ( a ) y < –3 and ( b ) x < 2 in a coordinate plane. Test the point (0,0). Because (0,0) is.
Supplementary Figure Legends Supplementary Figure 1: The variance of pD  H activity plotted against mean pD  H activity for three populations, obtained.

Supplementary Figure Legends Supplementary Figure 1: The variance of pD  H activity plotted against mean pD  H activity for three populations, obtained.
Math 51 3.5 Graphing Linear Inequalities in Two Variables 1.

Math Graphing Linear Inequalities in Two Variables 1.
EXAMPLE 2 Graph a linear inequality in two variables Graph the inequality y > 4x – 3. STEP 2 0 > 4(0) – 3 ? Test (0, 0) in y > 4x – 3. SOLUTION Graph the.

EXAMPLE 2 Graph a linear inequality in two variables Graph the inequality y > 4x – 3. STEP 2 0 > 4(0) – 3 ? Test (0, 0) in y > 4x – 3. SOLUTION Graph the.
Effects of inhibiting inflammatory cell recruitment on fracture healing Treatment with CCR2 antagonist, INCB3344, led to impaired fracture healing compared.

Effects of inhibiting inflammatory cell recruitment on fracture healing Treatment with CCR2 antagonist, INCB3344, led to impaired fracture healing compared.
Copyright © 2011 American Medical Association. All rights reserved.

Copyright © 2011 American Medical Association. All rights reserved.
Linear Inequalities Solution to inequality in one variable – interval on number line Solution to inequality in two variables – points in the plane Graph.

Linear Inequalities Solution to inequality in one variable – interval on number line Solution to inequality in two variables – points in the plane Graph.
Colocalization of the human trimethylguanosine synthase 1 and survival of motor neuron proteins. Colocalization of the human trimethylguanosine synthase.

Colocalization of the human trimethylguanosine synthase 1 and survival of motor neuron proteins. Colocalization of the human trimethylguanosine synthase.
Total and cause-specific mortality before and after the onset of the Greek economic crisis: an interrupted time-series analysis  Ioannis Laliotis, PhD,

Total and cause-specific mortality before and after the onset of the Greek economic crisis: an interrupted time-series analysis  Ioannis Laliotis, PhD,
(A, B) Stereoscopic views of the P3 RNase MRP RNA domain in complex with the RNase MRP/RNase P protein components Pop6 and Pop7. (A, B) Stereoscopic views.

(A, B) Stereoscopic views of the P3 RNase MRP RNA domain in complex with the RNase MRP/RNase P protein components Pop6 and Pop7. (A, B) Stereoscopic views.
Tariq Shafi, Andrew S. Levey  Advances in Chronic Kidney Disease 

Tariq Shafi, Andrew S. Levey  Advances in Chronic Kidney Disease 
The gene encoding TP53INP1 is expressed in pancreatic endocrine cells A, B(A, B) Immunocytofluorescent staining of TP53INP1 (red) and insulin (green) in.

The gene encoding TP53INP1 is expressed in pancreatic endocrine cells A, B(A, B) Immunocytofluorescent staining of TP53INP1 (red) and insulin (green) in.
The origins of age-related proinflammatory state

The origins of age-related proinflammatory state
Functional evaluation of ATR1 and PHO84 genes located at ePTL13.

Functional evaluation of ATR1 and PHO84 genes located at ePTL13.
AAV8‐hAAT‐FGF21 treatment improves liver fibrosis

AAV8‐hAAT‐FGF21 treatment improves liver fibrosis
The differences in sedentary behaviour and physical activity levels between the CVD groups*. The differences in sedentary behaviour and physical activity.

The differences in sedentary behaviour and physical activity levels between the CVD groups*. The differences in sedentary behaviour and physical activity.
CAR T cell dose and percentages of CAR‐positive cells within CAR T cell products CAR T cell dose and percentages of CAR‐positive cells within CAR T cell.

CAR T cell dose and percentages of CAR‐positive cells within CAR T cell products CAR T cell dose and percentages of CAR‐positive cells within CAR T cell.
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Similar presentations

Ads by Google